1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Xiangxue Pharmaceutical Co.,Ltd.

Xiangxue Pharmaceutical Co.,Ltd.

300147.SZ
Xiangxue Pharmaceutical Co.,Ltd.CN flagShenzhen Stock Exchange
9.60
CNY
+0.20
- -
6.32BMarket Cap
Xiangxue Pharmaceutical Co.,Ltd.
300147.SZ
(Shenzhen Stock Exchange)

Recent

price

9.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.13
1.01
1.33
2.64
2.48
2.31
2.82
3.32
3.99
4.37
4.67
4.48
3.3
3.49
2.81
2.42
2.34
Revenue per Share
0.16
0.14
0.18
0.33
0.32
0.28
0.1
0.1
0.09
0.12
0.11
-1.02
-0.8
-0.59
-1.3
-2.11
-1.42
Basic EPS, GAAP
-0.03
-0.33
-0.5
0.02
-0.13
-0.18
-2.68
-1.01
-0.64
-0.91
-0.53
-0.37
-0.21
0.31
-0.03
0.18
-0.03
Free Cash Flow per Basic Share
0.14
0.09
0.13
0.31
0.24
0.21
0.24
0.26
0.33
0.38
0.31
0.33
0.27
0.21
0.08
0.01
- -
Dividend per Share
0.57
0.69
0.87
1.47
1.53
1.88
1.77
1.87
2.1
2.14
1.93
0.89
0.09
-0.49
-1.78
-3.89
-2.09
Book Value per Share
2.87
2.04
2.18
2.23
1.97
4.46
4.01
4.06
4.13
4.33
3.15
2.95
1.74
1.15
0.27
-1.72
-0.04
Tangible Book Value per Share
454
608
600
477
615
633
660
659
627
638
657
663
663
659
660
660
675
Basic Weighted Avg Shares
513
616
801
1,261
1,524
1,465
1,862
2,187
2,504
2,786
3,072
2,971
2,187
2,299
1,859
1,595
1,580
Sales/Revenue/Turnover
20.07
16.77
18.5
18.59
17.03
16.06
7.2
7.05
11.73
7.77
11.51
1.55
-6.56
5.96
-7.67
-4.8
-15.42
Operating Margin (%)
18
25
34
42
69
83
98
105
114
115
51
57
239
237
226
194
- -
Depreciation Expense
74
83
107
158
197
177
66
66
56
77
72
-677
-530
-389
-859
-1,392
-957
Net Income, GAAP
14.35
15.75
15.7
12.11
3.58
7.29
14.8
10.94
21.46
- -
16.68
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
14.45
13.55
13.38
12.55
12.91
12.11
3.55
3.01
2.25
2.75
2.35
-22.78
-24.24
-16.92
-46.19
-87.26
-60.58
Profit Margin (%)
932
754
985
479
111
1,564
-320
1,637
696
-163
-2,768
-3,268
-3,540
-3,337
-3,779
-4,566
-4,353
Working Capital
42
180
675
716
537
499
754
1,822
1,308
938
949
531
452
591
602
465
154
LT Debt
1,371
1,419
1,537
1,710
1,871
3,546
3,684
3,884
4,012
4,112
4,136
3,656
2,720
2,313
1,439
44
1,221
Total Equity
7.94
5.05
5.55
7.37
8.48
6.11
2.26
2.06
3.09
- -
3.97
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
17.39
14.37
10.86
11.21
11.74
9.72
3.26
3.45
2.62
- -
2.61
- -
- -
- -
- -
- -
- -
Return on Capital (%)
31.63
24.63
22.72
25.82
23.95
16.63
5.59
5.48
4.43
5.72
5.5
-72.69
-161.66
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,641
2,019
2,078
LT Borrowings
571
201
124
LT Finance Leases
31
30
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
661
661
661
Market Capitalization
6,968
3,874
5,615

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,603
1,601
1,610
Cash, Cash Equivalents & STI
132
58
96
Accounts Receivable, Net
810
908
903
Inventories
341
311
277
Total Current Liabilities
5,382
5,777
5,962
Payables & Accruals
- -
- -
- -
ST Debt
1,641
2,019
2,078
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-17.12%
-37.38%
-96.95%
Free Cash Flow
9.05%
-244.16%
-792.09%
Net Income, GAAP
-94.85%
-180.25%
62.15%
Sales/Revenue/Turnover
2.28%
-11.57%
-14.16%
Total Cash Common Dividend
-13.83%
-37.12%
-88.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
569
528
437
325
1,859
2025
421
397
449
- -
1,595
2026
354
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
- -
- -
- -
-1.3
2025
-0.13
- -
- -
- -
-2.11
2026
-0.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.08
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
GeNeuro S.A. (GNRO.PA)
Idorsia Ltd (IDIA.SW)
Virios Therapeutics, Inc. (VIRI)
Renovacor, Inc. (RCOR)
GreenLight Biosciences Holdings (GRNAW)
Axsome Therapeutics, Inc. (AXSM)
Business
Xiangxue Pharmaceutical Co., Ltd. (300147.SZ) develops, manufactures, and distributes pharmaceutical products with a focus on modern traditional Chinese medicines in China. The company offers proprietary Chinese medicines and Chinese medicine tablets; chemicals and small quantities of Western medicines; medical devices including Baiyun medical glue and Gaoxun medical catheters; functional health products and healthcare supplements such as antivirotic oral liquids under the Xiangxue brand; pharmaceutical distribution services; and innovative biopharmaceuticals featuring high-affinity T-cell receptor (TCR) cell therapies for tumors. Founded in 1997 and headquartered at No. 2 Jinfengyuan Road, Guangzhou Economic and Technological Development Zone, China, Xiangxue operates primarily in the domestic market as a national high-tech enterprise specializing in traditional Chinese medicine modernization, biomedical engineering, and life sciences research. Recent developments include pre-reorganization approval by the Guangzhou Intermediate Court with appointment of a temporary administrator; progression of TCR-T therapies through subsidiary Xiangxue Life Sciences, including visits from partners like Leman Biotech; and involvement in 2024 events such as teacher support programs, back-to-school initiatives with pharmacies, and basketball league sponsorships to bolster brand health initiatives.